VENCLEXTA Film-coated Tablet
Venetoclax
100 mg
BRISTOL MYERS SQUIBB (EPERNON)
| Pack size | 120's Pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 258.50 AED |
Available as:
Indications
VENCLEXTA Film-coated Tablet is used for:
For the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Venetoclax :
Mechanism of Action
Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutics. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2.
Note
VENCLEXTA 100 mg Film-coated Tablet manufactured by BRISTOL MYERS SQUIBB (EPERNON). Its generic name is Venetoclax. VENCLEXTA is availble in Saudi Arabia.
Farmaco SA drug index information on VENCLEXTA Film-coated Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.